Search Site

Trends banner

ADNOC Drilling H1 revenue $2.37bn

The company posted a net profit of $692m.

Eni profit falls due to dip in oil prices

Q2 net profit fell by 18% to $637 million.

Emirates NBD H1 profit $3.40bn

Total income rose by 12 percent in the same period.

ADIB H1 pre-tax profit $1.08bn

Q2 pre-tax net profit increases by 14 percent.

AstraZeneca to invest $50bn in US

Bulk of funds to go into a Virginia manufacturing center.

Vaccine factory to come up in Khazaen City with $52m outlay

The rise in producer price index was driven by a hike in oil and gas prices.
  • The agreement was signed by Khazaen CEO Salim Al Thuhli and Opal’s Chairman of the Board of Directors, Sa’ad Moosa Al Junaibi
  • Al Thuhli was quoted by the official sources as saying that the project would be the first vaccine factory in Khazaen Economic City

The Khazaen Economic City in Oman has signed an agreement with biopharmaceuticals business company Opal to establish a factory for the production of biological human vaccines, official sources have said.

The deal was signed in Muscat on Wednesday, and has an outlay of OMR20 million (around $52 million), said the sources.

The first phase of the project is expected to be set up on a total area of 37,000 square meters.

The agreement was signed by Khazaen CEO Salim Al Thuhli and Opal’s Chairman of the Board of Directors, Sa’ad Moosa Al Junaibi.

Al Thuhli was quoted by the official sources as saying that the project would be the first vaccine factory in Khazaen Economic City.

He added that it targets local and international markets.

The agreement, Al Thuhli added, comes as part of Khazaen’s efforts in attracting local and international investments.